World Library  
Flag as Inappropriate
Email this Article

Mycobacterium avium complex

Article Id: WHEBN0004179752
Reproduction Date:

Title: Mycobacterium avium complex  
Author: World Heritage Encyclopedia
Language: English
Subject: Pathogenic bacteria, Tuberculosis, Rapid growing mycobacterium, Index of HIV/AIDS-related articles, Nontuberculous mycobacteria
Collection: Bacterial Diseases, Nontuberculous Mycobacteria
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Mycobacterium avium complex

Mycobacterium avium complex (MAC) is a group of genetically related bacteria belonging to the genus Mycobacterium. It includes Mycobacterium avium and Mycobacterium intracellulare.[1][2]

Some sources also include Mycobacterium avium subspecies paratuberculosis (MAP).[3]

Mycobacterium avium complex (MAC) include ubiquitous atypical bacteria found in the environment which can infect patients with HIV and low CD4 cell count (below 100/microliter); mode of infection is usually inhalation or ingestion.

MAC causes disseminated disease in up to 40% of patients with human immunodeficiency virus (HIV) in the United States, producing fever, sweats, weight loss, and anemia.[4][5][6] Disseminated MAC characteristically affects patients with advanced HIV disease and peripheral CD4+ T-lymphocyte counts less than 100 cells/uL. Effective prevention and therapy of MAC has the potential to contribute substantially to improved quality of life and duration of survival for HIV-infected persons.[7]

Contents

  • Diagnosis 1
  • Prevention 2
  • Treatment 3
    • HIV-infected children 3.1
  • See also 4
  • References 5

Diagnosis

Disseminated MAC is most readily diagnosed by one positive blood culture. Blood cultures should be performed in patients with symptoms, signs, or laboratory abnormalities compatible with mycobacterium infection. Blood cultures are not routinely recommended for asymptomatic persons, even for those who have CD4+ T-lymphocyte counts less than 100 cells/uL.[7]

Prevention

Patients with HIV infection and less than 50 CD4+ T-lymphocytes/uL should be administered prophylaxis against MAC. Prophylaxis should be continued for the patient's lifetime unless multiple drug therapy for MAC becomes necessary because of the development of MAC disease.[7]

Clinicians must weigh the potential benefits of MAC prophylaxis against the potential for toxicities and drug interactions, the cost, the potential to produce resistance in a community with a high rate of tuberculosis, and the possibility that the addition of another drug to the medical regimen may adversely affect patients' compliance with treatment. Because of these concerns, therefore, in some situations rifabutin prophylaxis should not be administered.[7]

Before prophylaxis is administered, patients should be assessed to ensure that they do not have active disease due to MAC, M. tuberculosis, or any other mycobacterial species. This assessment may include a chest radiograph and tuberculin skin test.[7]

Rifabutin, 300 mg by mouth daily, is recommended for the patient's lifetime unless disseminated MAC develops, which would then require multiple drug therapy. Although other drugs, such as azithromycin and clarithromycin, have laboratory and clinical activity against MAC, none has been shown in a prospective, controlled trial to be effective and safe for prophylaxis. Thus, in the absence of data, no other regimen can be recommended at this time.The 300-mg dose of rifabutin has been well tolerated. Adverse effects included neutropenia, thrombocytopenia, rash, and gastrointestinal disturbances.[7]

Treatment

Although studies have not yet identified an optimal regimen or confirmed that any therapeutic regimen produces sustained clinical benefit for patients with disseminated MAC, the Task Force concluded that the available information indicated the need for treatment of disseminated MAC. The Public Health Service therefore recommends that regimens be based on the following principles:[7]

  • Treatment regimens outside a clinical trial should include at least two agents.
  • Every regimen should contain either azithromycin or clarithromycin; many experts prefer ethambutol as a second drug. Many clinicians have added one or more of the following as second, third, or fourth agents: clofazimine, rifabutin, rifampin, ciprofloxacin, and in some situations amikacin. Isoniazid and pyrazinamide are not effective for the therapy of MAC.
  • Therapy should continue for the lifetime of the patient if clinical and microbiologic improvement is observed.

Clinical manifestations of disseminated MAC—such as fever, weight loss, and night sweats—should be monitored several times during the initial weeks of therapy. Microbiologic response, as assessed by blood culture every 4 weeks during initial therapy, can also be helpful in interpreting the efficacy of a therapeutic regimen.Most patients who ultimately respond show substantial clinical improvement in the first 4–6 weeks of therapy. Elimination of the organisms from blood cultures may take somewhat longer, often requiring 4–12 weeks.[7]

HIV-infected children

HIV-infected children less than 12 years of age also develop disseminated MAC. Some age adjustment is necessary when clinicians interpret CD4+ T-lymphocyte counts in children less than 2 years of age. Diagnosis, therapy, and prophylaxis should follow recommendations similar to those for adolescents and adults.[7]

See also

References

 This article incorporates public domain material from the Centers for Disease Control and Prevention document for Adults and Adolescents Infected with Human Immunodeficiency Virus"Mycobacterium avium Complex"Recommendations on Prophylaxis and Therapy for Disseminated .

  1. ^ White, Lois (2004). Foundations of Nursing. Cengage Learning. p. 1298.  
  2. ^ "Mycobacterium avium Complex"Disease Listing, . CDC Bacterial, Mycotic Diseases. Retrieved 2010-11-04. 
  3. ^ Irving, Peter; Rampton, David; Shanahan, Fergus (2006). Clinical dilemmas in inflammatory bowel disease. Wiley-Blackwell. p. 36.  
  4. ^ Horsburgh CR (May 1991). infection in the acquired immunodeficiency syndrome"Mycobacterium avium complex". N. Engl. J. Med. 324 (19): 1332–8.  
  5. ^ Chaisson RE, Moore RD, Richman DD, Keruly J, Creagh T (August 1992). infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group"Mycobacterium avium-complex"Incidence and natural history of . Am. Rev. Respir. Dis. 146 (2): 285–9.  
  6. ^ Havlik JA, Horsburgh CR, Metchock B, Williams PP, Fann SA, Thompson SE (March 1992). infection: clinical identification and epidemiologic trends"Mycobacterium avium complex"Disseminated . J. Infect. Dis. 165 (3): 577–80.  
  7. ^ a b c d e f g h i U.S. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex (June 1993). for adults and adolescents infected with human immunodeficiency virus"Mycobacterium avium complex"Recommendations on prophylaxis and therapy for disseminated . MMWR Recomm Rep 42 (RR-9): 14–20.  
  • "Mycobacterium avium complex". NCBI Taxonomy Browser. 37162. 
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.